S&P 500 may face selling pressure as systematic funds reach full exposure
Jonathan Siegal, Principal Accounting Officer at Vericel Corp (NASDAQ:VCEL), executed a series of stock transactions as disclosed in a recent SEC filing. On February 5, Siegal sold 1,092 shares of Vericel common stock at a price of $61.99 per share, totaling approximately $67,693. This transaction was part of an automatic sale under a pre-established Rule 10b5-1 trading plan. The sale occurred near Vericel’s 52-week high of $63.00, with the company currently valued at $2.9 billion. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $60 to $72.
In a separate transaction on the same day, Siegal exercised stock options to acquire 1,092 shares at an exercise price of $48.8 per share. Following these transactions, Siegal holds 1,206 shares of Vericel common stock. InvestingPro analysis shows the company maintains a "GOOD" overall financial health score, with particularly strong price momentum over the past six months. Discover 12 additional exclusive ProTips and comprehensive analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Vericel Corporation has been a focal point for several analyst firms following its recent preannouncement of Q4 2024 results and guidance for 2025. Canaccord Genuity raised its price target for Vericel from $64 to $67, citing strong mid-term targets related to margins and profitability. The firm’s new target is based on Vericel’s projected revenue for 2026, estimated to reach $352.6 million.
H.C. Wainwright also reaffirmed a Buy rating and a $60.00 price target for Vericel, despite Q4 revenues falling short of expectations. The firm highlighted the positive trend with Vericel’s MACI product, which remains a key revenue contributor. Additionally, Vericel’s burn franchise is projected to contribute $52.1 million in revenue in 2025.
On the other hand, Canaccord Genuity restated their Buy rating on Vericel shares, maintaining a price target of $64.00, despite preliminary revenue figures for Q4 2024 falling short of both Canaccord’s and consensus estimates. The company anticipates a 20% increase over the fiscal year 2023, with projected total revenue growth of 20-23% for 2025.
Lastly, Truist Securities raised its price target on Vericel to $67.00, reflecting confidence in Vericel’s growth trajectory and potential for increased revenue and profitability in the coming years. This comes as Vericel continues to develop its portfolio of treatments, focusing on addressing unmet medical needs through the commercialization of novel cell therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.